Identification
- Summary
Iron is an essential element commonly used for the treatment of patients with documented iron deficiency.
- Brand Names
- Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, Ferralet 90, Ferraplus, Natafort, Vitafol-one
- Generic Name
- Iron
- DrugBank Accession Number
- DB01592
- Background
A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Iron (DB01592)
- Weight
- Average: 55.845
Monoisotopic: 55.934942133 - Chemical Formula
- Fe
- Synonyms
- Carbonyl iron
- Eisen
- Electrolytic iron
- Fe
- fer
- Ferrum
- Ferrum metallicum
- Hierro
- Iron powder
- Iron, carbonyl
- Iron, electrolytic
- Iron, elemental
- Iron, reduced
- Reduced iron
Pharmacology
- Indication
Used in preventing and treating iron-deficiency anemia.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.
- Mechanism of action
Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.
Target Actions Organism UTransferrin receptor protein 1 Not Available Humans UEgl nine homolog 1 Not Available Humans UHistone deacetylase 8 cofactorHumans UAlpha-hemoglobin-stabilizing protein Not Available Humans UHemoglobin subunit alpha Not Available Humans UFrataxin, mitochondrial Not Available Humans UFerritin heavy chain Not Available Humans UFlap endonuclease 1 Not Available Humans UEndonuclease 8-like 1 Not Available Humans UEndonuclease 8-like 2 Not Available Humans UDNA polymerase beta Not Available Humans UCeruloplasmin Not Available Humans USerotransferrin Not Available Humans - Absorption
The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Acute iron overdosage can be divided into four stages. In the first stage, which occurs up to six hours after ingestion, the principal symptoms are vomiting and diarrhea. Other symptoms include hypotension, tachycardia and CNS depression ranging from lethargy to coma. The second phase may occur at 6-24 hours after ingestion and is characterized by a temporary remission. In the third phase, gastrointestinal symptoms recur accompanied by shock, metabolic acidosis, coma, hepatic necrosis and jaundice, hypoglycemia, renal failure and pulmonary edema. The fourth phase may occur several weeks after ingestion and is characterized by gastrointestinal obstruction and liver damage. In a young child, 75 milligrams per kilogram is considered extremely dangerous. A dose of 30 milligrams per kilogram can lead to symptoms of toxicity. Estimates of a lethal dosage range from 180 milligrams per kilogram and upwards. A peak serum iron concentration of five micrograms or more per ml is associated with moderate to severe poisoning in many.
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlmasilate Almasilate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. Benazepril The risk or severity of adverse effects can be decreased when Iron is combined with Benazepril. Calcium phosphate dihydrate Iron can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Captopril The risk or severity of adverse effects can be decreased when Iron is combined with Captopril. Carbidopa Iron can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy. Cefdinir Iron can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy. Cilazapril The risk or severity of adverse effects can be decreased when Iron is combined with Cilazapril. Cimetidine Cimetidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with or without food. Many different products contain iron; refer to the product monograph for more specific instruction. Taking iron with food may reduce gastric irritation.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Ferrous cation ionic GW89581OWR 15438-31-0 CWYNVVGOOAEACU-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Ed-In-Sol / Fe-40 / Feosol (GlaxoSmithkline) / Feostat / Fer-In-Sol / Feratab (Upsher-Smith) / Ferate / Fergon / Ferralet / Ferretts / Ferro sanol / Ferro-Caps / Ferro-Time / Ferrousal / Siderol / Simron / Slow Fe / Vitedyn-Slo / Yieronia
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Iron Chews Tablet, chewable 15 mg/1 Oral Mayne Pharma 2009-01-01 2016-12-31 US 
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Chelated Iron 25mg - Caplet Tablet 25 mg Oral Health Wise Nutrition Inc. 1995-12-31 2002-07-18 Canada 
Chelated Iron Supplement - Tab Tablet 18 mg Oral Albion 1996-09-06 2002-09-30 Canada Chelated Iron Tab 25mg Tablet 25 mg Oral Gahler Enterprises Ltd. 1984-12-31 2008-07-17 Canada Fe-chelate Tab Tablet 28 mg Oral Nutri West Products Ltd. 1994-12-31 1997-08-05 Canada Fera Liq 16.7mg/15ml Liquid 16.7 mg / 15 mL Oral Inno Vite Incorporated 1987-12-31 2007-07-31 Canada FERROCYTE TABLET 50 mg Tablet, film coated 50 mg Oral EISAI (SINGAPORE) PTE. LTD. 1991-06-17 Not applicable Singapore Iron Capsule 40 mg Oral Seroyal International Inc. 1994-12-31 2008-10-09 Canada Iron Amino Chelate Tab 37mg Tablet 37 mg Oral Pure Life International Prods Inc. 1992-12-31 2000-07-27 Canada Iron Chelate 25 mg Tablet 25 mg Oral Wn Pharmaceuticals Ltd. 2002-03-13 2006-08-08 Canada Iron Proteinate Chelate Tab 25mg Tablet 25 mg / tab Oral Country Health Laboratories Ltd. 1982-12-31 2001-07-27 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Actyform Iron (4.18 mg) + Copper (1 mg) + Magnesium (61.15 mg) + Zinc (9 mg) Capsule Oral Technodiet S.E.N.C. 1999-10-26 2008-08-13 Canada Advanced B & T Formula Iron (1.67 mg) + Ascorbic acid (33.3 mg) + Calcium (200 mg) + Chromium (33.33 mcg) + Copper (0.5 mg) + Cyanocobalamin (6.67 mcg) + Folic acid (0.133 mg) + Magnesium (83.3 mg) + Manganese (3.33 mg) + Nicotinamide (6.67 mg) + Calcium pantothenate (5 mg) + Phosphorus (100 mg) + Potassium (16.67 mg) + Pyridoxine hydrochloride (6.67 mg) + Riboflavin (2.67 mg) + Selenium (33.33 mcg) + Silicon (0.333 mg) + Sodium molybdate (16.67 mcg) + Thiamine (2.67 mg) + Vanadium (8.33 mg) + Vitamin D (66.67 unit) + Zinc (5 mg) Capsule Oral Nutraceutical Corporation Not applicable Not applicable Canada Calcium Et Magnesium Plus Vitamine D/fe/zn Iron (10 mg) + Calcium (400 mg) + Magnesium (167 mg) + Vitamin D (220 unit) + Zinc (10 mg) Tablet Oral Laboratoire Lalco Inc. 1993-12-31 2008-07-29 Canada Chela Iron Plus C,b Complex Iron (50 mg) + Calcium ascorbate (100 mg) + Copper (2 mg) + Cyanocobalamin (30 mcg) + Folic acid (.4 mg) + Iodine (100 mcg) + Manganese (2 mg) + Nicotinamide (15 mg) + Pantothenic acid (15 mg) + Pyridoxine hydrochloride (5 mg) + Riboflavin (2 mg) + Thiamine hydrochloride (5 mg) Tablet Oral Nu Life Nutrition Ltd. 1986-12-31 2000-03-03 Canada Chelamins Plus Tab Iron (15 mg) + Calcium (350 mg) + Chromium (50 mcg) + Copper (1.5 mg) + Iodine (.15 mg) + Magnesium (175 mg) + Manganese (5 mg) + Phosphorus (75 mg) + Potassium (47.5 mg) + Selenium (25 mcg) + Vitamin D (200 unit) + Zinc (11.25 mg) Tablet Oral Nu Life Nutrition Ltd. 1988-12-31 2000-03-03 Canada Children's Chewable Multi-vitamin Complete With Minerals Iron (4 mg / tab) + Ascorbic acid (50 mg / tab) + Biotin (30 mcg / tab) + Calcium (160 mg / tab) + Cholecalciferol (400 unit / tab) + Copper (1 mg / tab) + Cyanocobalamin (3 mcg / tab) + Folic acid (0.1 mg / tab) + Nicotinamide (15 mg / tab) + Calcium pantothenate (10 mg / tab) + Pyridoxine hydrochloride (1 mg / tab) + Riboflavin (1.5 mg / tab) + Thiamine hydrochloride (1.5 mg / tab) + Vitamin A palmitate (5000 unit / tab) + alpha-Tocopherol acetate (10 unit / tab) Tablet Oral Wn Pharmaceuticals Ltd. 2000-03-01 2001-07-18 Canada Children's Chewable Vit and Min Tab Iron (5 mg) + Ascorbic acid (100 mg) + Beta carotene (5000 unit) + Biotin (10 mcg) + Calcium citrate (65 mg) + Cholecalciferol (400 unit) + Choline bitartrate (5 mg) + Cyanocobalamin (10 mcg) + Folic acid (.2 mg) + Inositol (5 mg) + Magnesium (25 mg) + Manganese (1 mg) + Nicotinamide (10 mg) + Calcium pantothenate (10 mg) + Potassium citrate (5 mg) + Pyridoxine hydrochloride (5 mg) + Riboflavin (5 mg) + Thiamine hydrochloride (5 mg) + Vitamin E (25 unit) + Zinc citrate (2 mg) Tablet Oral Gahler Enterprises Ltd. 1990-12-31 2002-09-11 Canada Childrens Chewab Vitamin W Chel Minerals Iron (5 mg) + Ascorbic acid (75 mg) + Biotin (50 mcg) + Cyanocobalamin (10 mcg) + D-alpha-Tocopherol acetate (25 unit) + Folic acid (10 mcg) + Iodine (1 mg) + Nicotinamide (10 mg) + Pantothenic acid (10 mg) + Pyridoxine (5 mg) + Riboflavin (5 mg) + Thiamine (5 mg) + Vitamin A (5000 unit) + Vitamin D (400 unit) Tablet Oral Anabolic Laboratories Inc. 1981-12-31 1996-10-02 Canada CitraNatal 90 DHA Iron (90 mg/1) + Ascorbic acid (120 mg/1) + Calcium citrate tetrahydrate (160 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Potassium triiodide (150 ug/1) + Pyridoxine hydrochloride (20 mg/1) + Riboprine (3.4 mg/1) + Thiamine chloride (3 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet Oral Mission Pharmacal 2010-02-01 Not applicable US CitraNatal DHA Iron (27 mg/1) + Ascorbic acid (120 mg/1) + Calcium citrate tetrahydrate (125 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine chloride (3 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet Oral Mission Pharmacal 2007-11-20 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Active FE Iron (75 mg/1) + Ascorbic acid (160 mg/1) + Beta carotene (2100 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (30 ug/1) + DL-alpha tocopheryl acetate (40 [iU]/1) + Folic acid (1250 ug/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (4 mg/1) + Thiamine hydrochloride (4 mg/1) + Zinc oxide (20 mg/1) Tablet Oral Gm Pharmaceuticals 2013-11-11 Not applicable US Active OB Iron (20 mg/1) + Ascorbic acid (100 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (2 mg/1) + Cyanocobalamin (30 ug/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Doconexent (320 mg/1) + Folic acid (1 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (2 mg/1) + Zinc oxide (30 mg/1) Capsule, liquid filled Oral Gm Pharmaceuticals 2013-10-28 2017-03-31 US BioFerr 90 Iron (88.5 mg/1) + Ascorbic acid (138 mg/1) + Cyanocobalamin (16.8 ug/1) + Docusate sodium (55 mg/1) + Ferrous gluconate dihydrate (13.2 mg/1) + Folic acid (1.4 mg/1) Tablet, film coated Oral Biocomp Pharma, Inc. 2014-07-01 Not applicable US BumP DHA Iron (15 mg/1) + Cobamamide (500 mg/1) + Flavin adenine dinucleotide (1 mg/1) + Flavin mononucleotide (2 mg/1) + Leucovorin (1 mg/1) + Levomefolate magnesium (1 mg/1) + Magnesium oxide (125 mg/1) + NADH (25 ug/1) + Omega-3 fatty acids (300 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxal phosphate (5 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Zinc glycinate (15 1/1) Capsule Oral Centurion Labs 2017-03-24 2017-04-17 US Cavan Alpha Iron (27 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium carbonate (230 mg/1) + Cholecalciferol (800 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (220 ug/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (300 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1) Kit Oral Seton Pharmaceuticals 2010-07-01 2013-09-30 US Cavan Heme OB Iron (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Niacin (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Sodium selenate (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (15 mg/1) + alpha-Tocopherol succinate (10 [iU]/1) Tablet Oral Seton Pharmaceuticals 2010-08-03 2012-06-10 US Cavan One Iron (20 mg/1) + Calcium (150 mg/1) + Calcium ascorbate dihydrate (25 mg/1) + Cholecalciferol (170 [iU]/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (260 mg/1) + Ferrous asparto glycinate (7 mg/1) + Folic acid (1 mg/1) + Icosapent (40 mg/1) + Linoleic acid (30 mg/1) + Pyridoxine hydrochloride (25 mg/1) + alpha-Linolenic acid (30 mg/1) Capsule, gelatin coated Oral Seton Pharmaceuticals 2009-10-30 2011-11-27 US Centratex Iron (106 mg/1) + Cupric sulfate (0.8 mg/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Magnesium sulfate (6.9 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Sodium ascorbate (200 mg/1) + Thiamine mononitrate (10 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1) Capsule Oral Centurion Labs, LLC 2009-06-14 Not applicable US CitraNatal 90 DHA Iron (90 mg/1) + Ascorbic acid (120 mg/1) + Calcium citrate tetrahydrate (160 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Potassium triiodide (150 ug/1) + Pyridoxine hydrochloride (20 mg/1) + Riboprine (3.4 mg/1) + Thiamine chloride (3 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet Oral Mission Pharmacal 2010-02-01 Not applicable US CitraNatal 90 DHA Iron (85 mg/1) + Ascorbic acid (120 mg/1) + Calcium citrate tetrahydrate (159 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Ferrous gluconate dihydrate (5 mg/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine chloride (3 mg/1) + Thiamine mononitrate (4.54 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet Oral Mission Pharmacal Company 2014-04-11 Not applicable US
Categories
- ATC Codes
- B03AE02 — Iron, multivitamins and folic acid
- B03AE — Iron in other combinations
- B03A — IRON PREPARATIONS
- B03 — ANTIANEMIC PREPARATIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- A11AA — Multivitamins with minerals
- A11A — MULTIVITAMINS, COMBINATIONS
- A11 — VITAMINS
- A — ALIMENTARY TRACT AND METABOLISM
- B03AE — Iron in other combinations
- B03A — IRON PREPARATIONS
- B03 — ANTIANEMIC PREPARATIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- B03AE — Iron in other combinations
- B03A — IRON PREPARATIONS
- B03 — ANTIANEMIC PREPARATIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous metal compounds
- Class
- Homogeneous transition metal compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous transition metal compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous transition metal
- Molecular Framework
- Not Available
- External Descriptors
- elemental iron (CHEBI:82664)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- E1UOL152H7
- CAS number
- 7439-89-6
- InChI Key
- XEEYBQQBJWHFJM-UHFFFAOYSA-N
- InChI
- InChI=1S/Fe
- IUPAC Name
- iron
- SMILES
- [Fe]
References
- Synthesis Reference
Walter Lugscheider, Paul Mullner, Wilhelm Schiffer, Alois Leutgob, "Arrangement for producing metals, such as molten pig iron, steel pre-material and ferroalloys." U.S. Patent US4617671, issued 0000.
US4617671- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015531
- KEGG Compound
- C00023
- PubChem Compound
- 23925
- PubChem Substance
- 46509190
- ChemSpider
- 22368
- 262150
- ChEBI
- 18248
- Therapeutic Targets Database
- DAP001313
- PharmGKB
- PA450087
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Iron
- FDA label
- Download (100 KB)
- MSDS
- Download (75.6 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Heart Failure / Iron Deficiency (ID) / Systolic Left Ventricular Dysfunction 1 4 Completed Basic Science Anemia 1 4 Completed Diagnostic Anemia / Renal Failure, Chronic Renal Failure 1 4 Completed Health Services Research Pregnancy 1 4 Completed Prevention Anemia / Child Behavior Disorders / Cognitive Manifestations / Iron Deficiency (ID) 1 4 Completed Prevention Ferropenic Anemia / Risk of Hemoconcentration (Iron Levels >130g/L) 1 4 Completed Prevention Iron Deficiency (ID) 1 4 Completed Prevention Pregnancy Complications, Hematologic 1 4 Completed Treatment Anemia / Gastrointestinal Hemorrhage 1 4 Completed Treatment Chronic Kidney Disease (CKD) / Iron Deficiency Anemia (IDA) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Accucaps Industries Ltd.
- Breckenridge Pharmaceuticals
- Cardinal Health
- Centrix Pharmaceuticals
- Contract Pharm
- Cypress Pharmaceutical Inc.
- Dayton Pharmaceuticals
- Edwards Pharmaceuticals
- Equipharm Inc.
- Haupt Pharma
- Lehigh Valley Technologies Inc.
- Mallinckrodt Inc.
- Marlop Pharmaceuticals Inc.
- Midlothian Labs
- Nature's Bounty
- Physicians Total Care Inc.
- Provident Pharmaceuticals LLC
- Puretek Corp.
- Rising Pharmaceuticals
- River's Edge Pharmaceuticals
- Roxmar Laboratories
- Seyer Pharmatec Inc.
- Dosage Forms
Form Route Strength Injection, solution, concentrate Intravenous Solution Oral 6.66 mg Solution Oral 600 mg Tablet Oral 25 mg Tablet Oral 18 mg Solution Intravenous 100 mg Capsule, liquid filled Oral Capsule Oral Tablet Capsule Solution Intravenous Tablet, chewable Oral Tablet Oral 350 mcg Syrup Oral 1 g Tablet Oral 28 mg Solution Oral 50 mg Liquid Oral 16.7 mg / 15 mL Injection Intramuscular Tablet, extended release Oral Syrup Oral Tablet, film coated Oral 50 mg Solution Intramuscular Suspension Oral 30 mg Suspension Oral Gel Oral Capsule, delayed release Oral Tablet, delayed release Oral Tablet Oral Solution Intravenous 20 mg Elixir Oral Tablet, coated Oral Capsule Oral 40 mg Tablet Oral 37 mg Tablet, chewable Oral 15 mg/1 Tablet Oral 25 mg / tab Tablet Oral 40 mg Tablet, chewable Oral Solution / drops Oral Solution Oral 50 mg/ml Syrup Oral Injection, solution Intravenous Solution / drops Oral Solution Oral Powder, for solution Oral Liquid Oral Capsule Oral 50 mg/1 Liquid Oral 15 mg/1mL Solution Oral Tablet, coated Oral Capsule Oral 150 mg/1 Capsule, coated Oral Tablet Oral Capsule, gelatin coated Oral Tablet, effervescent Oral Solution Oral 40 MG/15ML Tablet, film coated Oral Tablet, chewable Oral 500 mg Injection Intravenous 100 mg/5ml Tablet, film coated Oral Kit Oral Suspension Oral 15 mg/1.25mL Injection, solution Intravenous 50 mg/1ml - Prices
Unit description Cost Unit Iron chews 15 mg tablet chew 0.29USD tablet Ferrous sulfate 28 mg tablet 0.04USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6667050 No 2003-12-23 2019-04-06 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 1538 °C Not Available - Predicted Properties
Property Value Source logP -0.77 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 0 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 0 m3·mol-1 ChemAxon Polarizability 1.78 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9838 Blood Brain Barrier + 0.9733 Caco-2 permeable + 0.7354 P-glycoprotein substrate Non-substrate 0.885 P-glycoprotein inhibitor I Non-inhibitor 0.9787 P-glycoprotein inhibitor II Non-inhibitor 0.9858 Renal organic cation transporter Non-inhibitor 0.9108 CYP450 2C9 substrate Non-substrate 0.8466 CYP450 2D6 substrate Non-substrate 0.8259 CYP450 3A4 substrate Non-substrate 0.8158 CYP450 1A2 substrate Non-inhibitor 0.8807 CYP450 2C9 inhibitor Non-inhibitor 0.9373 CYP450 2D6 inhibitor Non-inhibitor 0.9708 CYP450 2C19 inhibitor Non-inhibitor 0.9553 CYP450 3A4 inhibitor Non-inhibitor 0.988 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.882 Ames test Non AMES toxic 0.9633 Carcinogenicity Carcinogens 0.664 Biodegradation Ready biodegradable 0.7326 Rat acute toxicity 2.0135 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9547 hERG inhibition (predictor II) Non-inhibitor 0.9746
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Virus receptor activity
- Specific Function
- Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferri...
- Gene Name
- TFRC
- Uniprot ID
- P02786
- Uniprot Name
- Transferrin receptor protein 1
- Molecular Weight
- 84870.665 Da
References
- Hemadi M, Ha-Duong NT, El Hage Chahine JM: The mechanism of iron release from the transferrin-receptor 1 adduct. J Mol Biol. 2006 May 12;358(4):1125-36. Epub 2006 Mar 13. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Peptidyl-proline dioxygenase activity
- Specific Function
- Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific prol...
- Gene Name
- EGLN1
- Uniprot ID
- Q9GZT9
- Uniprot Name
- Egl nine homolog 1
- Molecular Weight
- 46020.585 Da
References
- Davidson TL, Chen H, Di Toro DM, D'Angelo G, Costa M: Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. Mol Carcinog. 2006 Jul;45(7):479-89. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Cofactor
- General Function
- Transcription factor binding
- Specific Function
- Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
- Gene Name
- HDAC8
- Uniprot ID
- Q9BY41
- Uniprot Name
- Histone deacetylase 8
- Molecular Weight
- 41757.29 Da
References
- Gantt SL, Gattis SG, Fierke CA: Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry. 2006 May 16;45(19):6170-8. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. Specifically protects free alpha-hemoglobin from precipitation. It is predicted to modulate pathological states of alpha-hemoglobin excess such as beta-thalassemia.
- Specific Function
- Hemoglobin binding
- Gene Name
- AHSP
- Uniprot ID
- Q9NZD4
- Uniprot Name
- Alpha-hemoglobin-stabilizing protein
- Molecular Weight
- 11840.325 Da
References
- Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ: Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006 Oct 27;281(43):32611-8. Epub 2006 Aug 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Oxygen transporter activity
- Specific Function
- Involved in oxygen transport from the lung to the various peripheral tissues.
- Gene Name
- HBA1
- Uniprot ID
- P69905
- Uniprot Name
- Hemoglobin subunit alpha
- Molecular Weight
- 15257.405 Da
References
- Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ: Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006 Oct 27;281(43):32611-8. Epub 2006 Aug 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1.
- Specific Function
- 2 iron, 2 sulfur cluster binding
- Gene Name
- FXN
- Uniprot ID
- Q16595
- Uniprot Name
- Frataxin, mitochondrial
- Molecular Weight
- 23134.895 Da
References
- Bencze KZ, Kondapalli KC, Cook JD, McMahon S, Millan-Pacheco C, Pastor N, Stemmler TL: The structure and function of frataxin. Crit Rev Biochem Mol Biol. 2006 Sep-Oct;41(5):269-91. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Iron ion binding
- Specific Function
- Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
- Gene Name
- FTH1
- Uniprot ID
- P02794
- Uniprot Name
- Ferritin heavy chain
- Molecular Weight
- 21225.47 Da
References
- Toussaint L, Bertrand L, Hue L, Crichton RR, Declercq JP: High-resolution X-ray structures of human apoferritin H-chain mutants correlated with their activity and metal-binding sites. J Mol Biol. 2007 Jan 12;365(2):440-52. Epub 2006 Oct 7. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structure-specific nuclease with 5'-flap endonuclease and 5'-3' exonuclease activities involved in DNA replication and repair. During DNA replication, cleaves the 5'-overhanging flap structure that is generated by displacement synthesis when DNA polymerase encounters the 5'-end of a downstream Okazaki fragment. It enters the flap from the 5'-end and then tracks to cleave the flap base, leaving a nick for ligation. Also involved in the long patch base excision repair (LP-BER) pathway, by cleaving within the apurinic/apyrimidinic (AP) site-terminated flap. Acts as a genome stabilization factor that prevents flaps from equilibrating into structurs that lead to duplications and deletions. Also possesses 5'-3' exonuclease activity on nicked or gapped double-stranded DNA, and exhibits RNase H activity. Also involved in replication and repair of rDNA and in repairing mitochondrial DNA.
- Specific Function
- 5'-3' exonuclease activity
- Gene Name
- FEN1
- Uniprot ID
- P39748
- Uniprot Name
- Flap endonuclease 1
- Molecular Weight
- 42592.635 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- NEIL1
- Uniprot ID
- Q96FI4
- Uniprot Name
- Endonuclease 8-like 1
- Molecular Weight
- 43683.625 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Involved in base excision repair of DNA damaged by oxidation or by mutagenic agents. Has DNA glycosylase activity towards 5-hydroxyuracil and other oxidized derivatives of cytosine with a preferenc...
- Gene Name
- NEIL2
- Uniprot ID
- Q969S2
- Uniprot Name
- Endonuclease 8-like 2
- Molecular Weight
- 36826.285 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Microtubule binding
- Specific Function
- Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that...
- Gene Name
- POLB
- Uniprot ID
- P06746
- Uniprot Name
- DNA polymerase beta
- Molecular Weight
- 38177.34 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ferroxidase activity
- Specific Function
- Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iro...
- Gene Name
- CP
- Uniprot ID
- P00450
- Uniprot Name
- Ceruloplasmin
- Molecular Weight
- 122204.45 Da
References
- Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transferrin receptor binding
- Specific Function
- Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
- Gene Name
- TF
- Uniprot ID
- P02787
- Uniprot Name
- Serotransferrin
- Molecular Weight
- 77063.195 Da
References
- Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. [Article]
Drug created at August 29, 2007 16:01 / Updated at June 26, 2022 10:21